Top Global CROs by Revenue

Top Global CROs by Revenue

The CRO industry has experienced remarkable growth over the past decade, driven by increasing pharmaceutical R&D spending, the complexity of modern drug development, and the increasing reliance on outsourced clinical trials. As biopharma companies seek to accelerate time-to-market while managing costs, they increasingly rely on CROs to handle everything from study design and patient recruitment to regulatory submissions and data management. This shift has created a highly competitive landscape where scale, geographic reach, and therapeutic expertise determine market leadership.

Revenue serves as a key indicator of a CRO's market position, reflecting not only their ability to win and execute large-scale clinical programs but also their operational capacity and client trust. The largest global CROs have built their dominance through strategic acquisitions, international expansion, and comprehensive service offerings that span the entire drug development lifecycle. From early-phase studies to post-market surveillance, these industry leaders have positioned themselves as indispensable partners to pharmaceutical companies worldwide, generating billions in annual revenue while advancing medical innovation across diverse therapeutic areas.

---

COG: CRO Summit brings together International leaders from Contract Research Organizations and functional service providers in the Raleigh-Durham Research Triangle to advance operational excellence and innovation in clinical trial delivery.

This premier two-day gathering delivers actionable insights on emerging technologies, strategic collaboration, and the evolving landscape of the global CRO industry.

Find Our More Here: https://www.thepbcgroup.com/crosummit

---

IQVIA

IQVIA Holdings Inc. remains the world's largest clinical research organization, headquartered in Durham, North Carolina. The company reported full-year 2025 revenue of $16.31 billion, up 5.9% year-over-year, extending its position as the undisputed leader in the global CRO market. Full-year GAAP net income was $1.36 billion, and adjusted EBITDA reached $3.79 billion.

IQVIA's segments continued to grow: Research & Development Solutions (R&DS) generated $8.9 billion for the full year (up 4.3%), while Technology & Analytics Solutions (TAS) delivered $6.63 billion (up 7.6%). R&DS ended the year with a contracted backlog of $32.7 billion, up 5.3% year-over-year, with roughly $8.3 billion expected to convert to revenue over the next twelve months. IQVIA has issued full-year 2026 revenue guidance of $17.15–$17.35 billion. The company continues to operate across more than 100 countries, with strength in oncology, immunology, and emerging markets throughout Latin America and Asia where pharmaceutical growth is accelerating rapidly.

Thermo Fisher Scientific

Thermo Fisher Scientific Inc. remains a major force in the CRO market through its clinical research division, PPD, acquired for $17.4 billion in 2021. The company reported full-year 2025 revenue of $44.56 billion, up 4% year-over-year, with GAAP diluted EPS of $17.74 and adjusted EPS of $22.87. Full-year adjusted operating income reached $10.11 billion, and free cash flow totaled $6.34 billion.

Headquartered in Waltham, Massachusetts, Thermo Fisher deployed roughly $16.5 billion in capital during 2025, including about $13 billion in M&A. Through its PPD clinical research division, the company provides comprehensive clinical development services across more than 20 therapeutic areas, with a substantial presence across North America, Europe, and Asia-Pacific. Management has guided to 2026 revenue of $46.3–$47.2 billion, representing 4–6% growth, citing continued strength in bioproduction and mid-single-digit growth in clinical research.

ICON

ICON plc, the Irish-headquartered global clinical research organization, reported full-year 2025 revenue of $8.25 billion, a modest 0.8% increase over the prior year (roughly flat at constant currency). Full-year adjusted EBITDA was $1.53 billion, or 18.6% of revenue.

It's worth noting that ICON's 2025 results were delayed: in February 2026 the company disclosed an Audit Committee investigation into certain accounting practices, with preliminary indications that 2023 and 2024 revenue may have been overstated by less than 2% in each year. The investigation, now concluded, did not identify any impact to customers. Looking ahead, ICON issued 2026 guidance of $7.85–$8.15 billion in revenue. The company continues to operate through a global network spanning 106 locations across 55 countries, with service delivery capability in a total of 93 countries through remote staff and third-party partnerships, and remains a top-tier player across North America, Europe, and Asia-Pacific.

Syneos Health

Syneos Health, taken private in August 2023 by a consortium including Elliott Investment Management, Patient Square Capital, and Veritas Capital, no longer discloses audited results publicly. Third-party estimates put trailing-twelve-month revenue at roughly $5.4–$6.1 billion as of early 2026, broadly in line with prior years — commentary from industry trackers describes revenue as largely flat to modestly growing since the take-private transaction. Reported headcount estimates vary by source, generally in the 20,000–27,000 range globally.

Based in Morrisville, North Carolina, Syneos Health continues to operate as a combined CRO/CCO (Contract Commercial Organization), supporting customers in more than 110 countries. The company has continued to invest in its integrated model under CEO Costa Panagos, with its communications and consulting arms — including Syneos Health Communications — reporting continued growth through 2025, and a global presence spanning North America, Europe, and Asia-Pacific, including operations in India, China, Singapore, and Japan.

Parexel

Parexel International Corporation, founded in 1982 and headquartered in Massachusetts and Durham, North Carolina, remains privately held under EQT and Goldman Sachs Asset Management following its 2021 take-private at $8.5 billion. As a private company, Parexel no longer publishes detailed financials; third-party estimates continue to place annual revenue in the $3.5–$4 billion range, with employee counts across different trackers ranging from roughly 18,000 to over 20,000 globally.

Parexel continues to operate a global network spanning six continents, with a strong footprint across North America and Asia-Pacific, including clinical trial supplies and logistics depots in China and Singapore. Through 2025 and into 2026, the company has continued to expand its AI-enabled clinical trial capabilities, including new partnerships and thought-leadership initiatives at major industry conferences such as DIA and ASCO, alongside its established presence across North America, Europe, Asia-Pacific, and Latin America.

Medpace

Medpace Holdings, Inc., the Cincinnati-based global CRO, delivered standout growth in 2025. Full-year revenue reached $2.53 billion, up 20.0% from 2024 — well ahead of the company's original guidance range. Full-year net income rose 11.6% to $451.1 million, and EBITDA grew 16.1% to $557.7 million, with diluted EPS of $15.28 (up 21.0%).

Medpace's headcount grew more modestly, up 5.7% year-over-year to 6,228 employees, suggesting notable productivity gains alongside the revenue growth. Backlog reached $3.03 billion by year-end, up 4.3%, with a backlog conversion rate that improved to 23.6%. The company also returned significant capital to shareholders, repurchasing $912.9 million of stock during the year. Founded in 1992 by former FDA reviewer Dr. August J. Troendle, Medpace continues to specialize in Phase I–IV clinical development for small and mid-sized biotech, pharmaceutical, and medical device companies, with a strong European presence through partnerships with organizations like the UK NIHR CRN and operations spanning Central and Eastern Europe, Israel, South Africa, Asia-Pacific, and Latin America. Medpace has guided to 2026 revenue of $2.76–$2.86 billion.